Hereditary Neuromuscular Diseases are rare multifactorial conditions difficult to ascertain; it’s noteworthy that 𝟲𝟬% of patients lack an accurate diagnosis. In Europe, 𝟱𝟬𝟬 𝘁𝗵𝗼𝘂𝘀𝗮𝗻𝗱 people suffer from these diseases, with 𝟯𝟬% of cases leading to permanent disability.
CoMPaSS-NMD proposes an innovative approach to diagnose these diseases based on Artificial Intelligence.
“The goal is to develop AI algorithms to improve the diagnosis of hereditary neuromuscular diseases,” explains Annalisa De Angelis, communication consultant at Deep Blue, partner of the project. “Due to being caused by various and complex genetic interactions, these pathologies are challenging for specialists to comprehend.”
“Hence, it is necessary to find a way to effectively use patient data to quickly understand what is happening and intervene promptly with an appropriate therapeutic plan,” emphasizes Rossella Tupler, genetist at Università degli Studi di Modena e Reggio Emilia, and project coordinator.
𝗖𝗼𝗠𝗣𝗮𝗦𝗦-𝗡𝗠𝗗 𝗮𝗶𝗺𝘀 𝘁𝗼 𝗱𝗲𝘃𝗲𝗹𝗼𝗽 𝗮 𝗽𝗮𝘁𝗶𝗲𝗻𝘁 𝗰𝗹𝗮𝘀𝘀𝗶𝗳𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝘀𝘆𝘀𝘁𝗲𝗺 𝘁𝗵𝗮𝘁 𝗹𝗲𝘃𝗲𝗿𝗮𝗴𝗲𝘀 𝗔𝗿𝘁𝗶𝗳𝗶𝗰𝗶𝗮𝗹 𝗜𝗻𝘁𝗲𝗹𝗹𝗶𝗴𝗲𝗻𝗰𝗲 𝘁𝗼 𝘀𝘂𝗽𝗽𝗼𝗿𝘁 𝗱𝗼𝗰𝘁𝗼𝗿𝘀, 𝗵𝗲𝗹𝗽𝗶𝗻𝗴 𝘁𝗵𝗲𝗺 𝗽𝗿𝗼𝗰𝗲𝘀𝘀 𝗵𝗶𝗴𝗵𝗹𝘆 𝗰𝗼𝗺𝗽𝗹𝗲𝘅 𝗱𝗮𝘁𝗮 𝗮𝗻𝗱 𝗾𝘂𝗶𝗰𝗸𝗹𝘆 𝘂𝗻𝗱𝗲𝗿𝘀𝘁𝗮𝗻𝗱 𝘁𝗵𝗲 𝗱𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰 𝗮𝗻𝗱 𝘁𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰 𝗱𝗶𝗿𝗲𝗰𝘁𝗶𝗼𝗻 𝘁𝗼 𝘁𝗮𝗸𝗲.
Deep Blue interviewed us and published an article on CoMPaSS-NMD on the corporate blog.
Read the full article (in italian) L’Intelligenza Artificiale per la diagnosi delle malattie neuromuscolari ereditarie